Autopsy report · NCT00180544

Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease

“Device superceded by next generation device. Enrollment stopped, long term follow up was completed in August of 2004.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 years 2 months after it had already started.
• Ran for about 4 years 1 month before it stopped.
• 167 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Abbott Medical Devices

Sponsor type

Industry

Conditions

Renal Artery Obstruction

Interventions

Stenting: Renal Artery

Participants

167

Sites

1

Countries

United States

Trials that died the same way

• Endurant Evo US Clinical Trial
  “This study terminated enrollment due to device failures prior to enrollment completion.” (69% match in meaning)
• Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
  “enrollment halted in order to have all patients complete follow-up by Jan 2011” (66% match in meaning)
• Inhaled Budesonide for Altitude Illness Prevention
  “Stopped prior to enrollment per PI and DSMB decision.” (65% match in meaning)
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
  “The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.” (65% match in meaning)
• Intraocular Pressure (IOP) Changes Associated With Muslim Prayer Postural Changes
  “Stopped due to low enrollment” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.